CAM™’s unique P-wave-centric ECG monitor offers unmatched signal clarity and superior arrhythmia detection
SANTA CLARA, Calif., May 6, 2019 /PRNewswire/ — Based on its recent analysis of the North American remote cardiac monitoring market, Frost & Sullivan recognizes Bardy Diagnostics, Inc. (BardyDx) with the 2019 North America Technology Innovation Award for its Carnation Ambulatory Monitor™ (CAM™) patch. The CAM™ patch is a first-of-its-kind P-wave-centric surface electrocardiograph (ECG) arrhythmia detection device that leverages state-of-the-art engineering and design to deliver groundbreaking monitoring.
“The patch’s use of advanced engineering and design allows it to detect different arrhythmias occurring at the same time, positively impacting patient management, especially when the arrhythmias may require different treatment decisions. For example, the CAM™ patch can accurately detect classic atrial flutter (AFL) and paroxysmal atrial fibrillation (PAF) occurrences. With a typical monitor, AFL may be obscured by AF presence, resulting in inadequate treatments and increased costs and risks to the patient,” said Kamaljit Behera, Industry Analyst at Frost & Sullivan. “BardyDX developed the CAM™ patch to provide optimal detection and clear recording of the often difficult to detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis and subsequent patient management.”
The CAM™ patch’s novel circuit design and signal capture technologies result in accurate and clear P-wave detection and recording. As a result, the CAM™ patch delivers improved ECG resolution and diagnostic accuracy while simultaneously providing continuous data on the heart’s rhythm.
In addition, CAM™ patch’s ease-of-use promotes patient compliance and streamlines clinical workflows. To simplify diagnostics and reporting further, BDxCONNECT, a companion patient management portal, provides healthcare professionals with a single system for creating, accessing, and managing patient CAM™ reports. Finally, BardyDx’s augmented intelligence and visualization technologies will accelerate information delivery and clinically meaningful insights to clinicians while enhancing operational efficiencies.
“These product benefits have earned the company a wide interest from investors, including some of the largest healthcare venture capital firms, and many of the top US health systems are already using the CAM™ patch. Furthermore, the device is one of only a few monitors suitable for pediatric applications,” noted Behera. “Overall, BardyDx’s thought leadership, unparalleled innovation, and disruptive potential have positioned it for greater adoption in the cardiac monitoring market.”
Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Bardy Diagnostics, Inc.
Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children weighing more than 10kg (22lbs) through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. For more information, please visit www.bardydx.com.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.
SOURCE Frost & Sullivan